Research

RAF Current Clinical Trials

DRY AMD—Geographic Atrophy:
DERBY/OAKS Trial: Apellis Pharmaceuticals
COMPARES: APL-2 inj Q1 or Q2 mos to sham inj Q1 or Q2 mos
ELIGIBILITY: patients with areas of geographic atrophy, VA 20/320 or better DURATION: pt is enrolled for 2 years
QUESTION: Will APL-2 prevent progression of GA

Brimo DDS: Allergan Pharmaceuticals
COMPARES: intravitreal Brimonidine biodegradable pellet Q 3mos vs sham injections Q3 mos ELIGIBILITY: patients with areas of geographic atrophy, VA 20/320 or better
DURATION: pt is enrolled for 2 years
QUESTION: Will Brimonidine pellet prevent progression of GA

WET AMD:
ARCHWAY Trial: Genentech/Roche Pharmaceuticals
COMPARES: Ranibizumab Port Delivery System (RPDS) Q 6mo refill vs Lucentis Q1 mo injections ELIGIBILITY: VA 20/400 or better. Diagnosed with WET AMD, less than 6 months treatment DURATION: pt is enrolled for 2 years
QUESTION: is RPDS with q6 month refills more effective than Lucentis monthly

LUCERNE Trial: Genentech/Roche Pharmaceuticals
COMPARES: faricimab (new drug) Q12-16 wks vs Eylea q8wk
ELIGIBILITY: VA 20/400 or better. Newly-diagnosed WET AMD with no prior treatment DURATION: pt is enrolled for 2 years
QUESTION: Is faricimab Q16 wks more effective than Eylea Q8 wks

DIABETIC MACULAR EDEMA:
YOSEMITE Trial: Genentech/Roche Pharmaceuticals
COMPARES: faricimab (new drug) q12-16 wk vs Eylea q8wk in pts with Diabetic Macular Edema ELIGIBILITY: Type 1 or 2, VA: 20/40-20/400, no DME treatment in the last 3 months
DURATION: pt is enrolled for 2 years
QUESTION: Is faricimab dosed Q16 wk more effective than Eylea dosed q8wk

Kingfisher Trial: Novartis Pharmaceuticals
COMPARES: Brolucizumab Q 4 wk injections vs Eylea Q4 wk injections
ELIGIBILITY: Type 1 or 2, VA: 20/40-20/320, no DME treatment in the last 3 months DURATION: pt is enrolled for 2 years
QUESTION: is Brolucizumab q4 wks noninferior to Eylea q4 wks

DIABETIC RETINOPATHY ± MACULAR EDEMA:
Lucentis Port Delivery System DR Trial: Genentech/Roche Pharmaceuticals
COMPARES: Ranibizumab Port Delivery System (RPDS) Q 6mo refill vs Eylea Q8 wk injections ELIGIBILITY: Type 1 or 2, VA: 20/20-20/400, NPDR-PDR ± Diabetic Macular Edema DURATION: pt is enrolled for 2 years
QUESTION: is RPDS with q6 month refills more effective than Eylea q8 wks in regression of Diabetic Retinopathy and Improvement of Macular Edema

We encourage you to refer potential patients for free screening as they would benefit from participation in these studies. The trials are sponsored, so eligible patients will NOT incur additional costs and transportation is provided if needed.

If you have a patient with one of these conditions, please call us to make their referral appointment and mention the clinical trial when making the appointment. Please complete our Clinical Trial Referral Form and ask your patient to bring with them to their appointment.

If you are working on a weekend or after 5:00pm, please complete the Clinical Trial Referral Form and fill it out, then FAX it to our office. We will then contact the patient to make the appointment.

For the initial evaluation, the patient will need to provide their own transportation. If they qualify for the trial, then future transportation will be provided by RAF (via Uber or Taxi).

Questions:
Janet Traynom
Study Coordinator
813-875-6373 ext 239
retinajt@tampabay.rr.com